The ASCO Post Podcast

Latest Episodes:

FDA Approvals in Esophageal Cancer and Follicular Lymphoma Jun 02, 2022

Show notes

Last week, the FDA approved treatments for esophageal cancer and follicular lymphoma. On this episode, we’ll review the data supporting those approvals and hear from researchers involved in the trials investigating the efficacy of these regimens.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approval for Newly Diagnosed Acute Myeloid Leukemia May 27, 2022

Show notes

This week, we’re covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we’ll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML

Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Reports From the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer May 20, 2022

Show notes

The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer was held recently in Phoenix, Arizona. On this episode, we’ll hear from two researchers who presented data at the meeting on ovarian and cervical cancers.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

MONALEESA-3: Updated Overall Survival Analysis May 13, 2022

Show notes

On this episode, we’ll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we’ll hear from a researcher about the current state of cancer research and anticipated trends in the field.

Coverage of stories discussed this week on ascopost.com:

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Adult Patients With Unresectable or Metastatic HER2-Positive Breast Cancer May 06, 2022

Show notes

On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with The ASCO Post at the 2021 San Antonio Breast Cancer Symposium.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

More From the AACR Annual Meeting 2022: Future Research Trends Apr 27, 2022

Show notes

On this episode, we’ll continue our coverage of the American Association for Cancer Research, or AACR, Annual Meeting. We’ll hear from three specialists on the future of cancer research and treatment; the development of novel therapeutic strategies to target DNA damage response; and an overview of the FDA’s accelerated approval program.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Data From the AACR Annual Meeting 2022 Apr 18, 2022

Show notes

The American Association for Cancer Research, or AACR, Annual Meeting took place from April 8 to 13 in New Orleans. The AACR Annual Meeting brings together the cancer research community to share the latest advances in cancer science and medicine, from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. On this episode of the podcast, we’ll hear from three researchers who presented data at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Highlights From the NCCN 2022 Annual Conference Apr 04, 2022

Show notes

The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we’ll hear from three speakers who discussed recent advances in cancer care in their respective fields.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approvals in Prostate and Endometrial Cancers Mar 29, 2022

Show notes

In this week’s episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approval in Germline BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer Mar 18, 2022

Show notes

In this week’s episode, we’ll discuss a recent FDA approval in germline BRCA-mutated, HER2-negative, high-risk early breast cancer. Then, we’ll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.